Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Subscribe for $2

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan

Overview
Profile
IX Biopharma Stock

IX Biopharma Stock 42C.SI

42C.SI
SG1BD9000009

Price

0.02
Today +/-
+0.00
Today %
+5.13 %

IX Biopharma stock price

Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IX Biopharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IX Biopharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IX Biopharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IX Biopharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IX Biopharma Stock Price History

DateIX Biopharma Price
8/15/20250.02 undefined
8/14/20250.02 undefined
8/13/20250.02 undefined
8/12/20250.02 undefined
8/11/20250.02 undefined
8/8/20250.02 undefined
8/7/20250.02 undefined
8/6/20250.02 undefined
8/5/20250.02 undefined
8/4/20250.02 undefined
8/1/20250.02 undefined
7/31/20250.02 undefined
7/30/20250.02 undefined
7/29/20250.02 undefined
7/28/20250.02 undefined
7/25/20250.02 undefined
7/24/20250.02 undefined
7/23/20250.02 undefined
7/22/20250.02 undefined
7/21/20250.02 undefined
7/18/20250.02 undefined
7/17/20250.02 undefined

IX Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IX Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IX Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IX Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IX Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IX Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IX Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IX Biopharma’s growth potential.

IX Biopharma Revenue, EBIT and net profit per share

DateIX Biopharma RevenueIX Biopharma EBITIX Biopharma Net Income
2025e24.28 M undefined0 undefined6.36 M undefined
20245.96 M undefined-6.98 M undefined-10.79 M undefined
20235.91 M undefined-8.45 M undefined-9.62 M undefined
202214.39 M undefined1.24 M undefined-4.6 M undefined
20211.75 M undefined-9.86 M undefined-8.23 M undefined
2020985,000 undefined-10.73 M undefined-10.5 M undefined
2019671,000 undefined-11.57 M undefined-2.99 M undefined
2018246,000 undefined-14.12 M undefined-15.09 M undefined
20176.38 M undefined-8.52 M undefined-7.39 M undefined
20165.8 M undefined-6.7 M undefined-7.7 M undefined
20157.45 M undefined-8.53 M undefined-10.56 M undefined
20141.29 M undefined-3.42 M undefined-3.03 M undefined
20130 undefined-1.71 M undefined-1.8 M undefined
20120 undefined-1.16 M undefined-1.15 M undefined

IX Biopharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20122013201420152016201720182019202020212022202320242025e
0017560001145524
---600.00-28.5720.00----1,300.00-64.29-380.00
--100.0085.7120.0033.33---100.0085.7140.0020.004.17
001612000012210
-1-1-3-10-7-7-15-2-10-8-4-9-106
--200.00233.33-30.00-114.29-86.67400.00-20.00-50.00125.0011.11-160.00
545.68545.68545.68522.54602.65646.18649.36651.67655.16695.25754.63773.57767.360
--------------
Details

Keystats

ⓘ

Revenue and Growth

The IX Biopharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IX Biopharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (k)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (k)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (k)
OTHER LIAB. (k)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2012201320142015201620172018201920202021202220232024
                         
0.378.4912.088.8931.3331.0921.0715.875.666.2113.496.531.84
000.671.330.820.930.830.040.150.220.51.251.29
00.190.510.414.062.041.21.381.151.591.481.81.63
0000000.530.850.881.10.910.961.38
203030306542521486362297227462435956
0.398.7113.2910.9336.7534.5824.1118.518.149.3516.8410.987.1
00.052.592.177.548.198.17.648.298.957.728.227.61
00000000002.263.870.01
0000000001.591.481.80
002.551.91.471.060.540.150.140.090.0400
00380335325343327308310327310291291
0000.060.020.0800.080.110.151.341.570.13
00.055.524.479.369.678.968.188.8411.113.1515.758.04
0.398.7618.8115.446.1144.2533.0726.6916.9820.453026.7315.14
                         
3.9210.8621.4429.026570.1371.1371.5372.2583.3494.1897.2397.45
0000000000000
-4.19-6.47-8.82-18.76-27.32-34.37-50.05-52.73-63.42-71.56-76-85.09-96.73
0.283.760.17-0.020.51-0.140.441.71.33-0.071.573.713.62
0000000000000
0.018.1512.7910.2438.1935.6321.5220.510.1711.7119.7415.854.34
0.160.340.390.611.160.883.620.470.850.550.220.45.48
0.070.220.931.721.432.022.651.591.852.122.082.412.39
0.140.051.321.690.630.70.580.270.140.22.021.180.85
0000000000000
001.090.080.210.270.290.210.460.83.533.192.88
0.370.613.734.13.423.877.132.533.33.677.867.1811.6
000.530.44.054.484.253.623.463.440.881.152.32
00880537356172900000716539
008901189710078366040423940
002.31.054.54.754.423.663.523.480.921.92.9
0.370.616.035.167.928.6311.556.196.817.158.779.0814.5
0.388.7618.8215.446.1144.2533.0726.6916.9818.8628.5224.9318.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IX Biopharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IX Biopharma's financial health and stability.

Assets

IX Biopharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IX Biopharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IX Biopharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IX Biopharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-1-1-3-10-7-7-15-2-10-8-4-9
000001,0001,0001,0001,0001,0001,0000
000000000000
0000045-31000
0002-2-20-80-160
000000000000
00000-4-100000
-1-1-2-6-9-4-8-13-8-83-7
0000-1-1-1-10000
000-1-2-1-1900-50
0010-1001100-50
000000000000
000000000000
09453540001092
09443440-101091
-----1.00---1.00----
000000000000
083-3220-10-5-1017-6
-1.03-1.67-2.29-6.86-10.29-5.28-9.55-15.59-9.31-8.912.92-8.36
000000000000

IX Biopharma stock margins

The IX Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IX Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IX Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IX Biopharma's sales revenue. A higher gross margin percentage indicates that the IX Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IX Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IX Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IX Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IX Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IX Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IX Biopharma Margin History

IX Biopharma Gross marginIX Biopharma Profit marginIX Biopharma EBIT marginIX Biopharma Profit margin
2025e17.59 %0 %26.18 %
202417.59 %-117.13 %-181.14 %
202339.24 %-142.84 %-162.61 %
202285.41 %8.6 %-31.95 %
2021-21.89 %-565.1 %-471.86 %
2020-59.59 %-1,089.54 %-1,065.89 %
2019-78.84 %-1,724.89 %-445.75 %
2018-100.41 %-5,741.06 %-6,135.77 %
201735.1 %-133.46 %-115.81 %
201629.45 %-115.58 %-132.88 %
201592.3 %-114.51 %-141.85 %
201493.02 %-265.12 %-234.88 %
201317.59 %0 %0 %
201217.59 %0 %0 %

IX Biopharma Stock Sales Revenue, EBIT, Earnings per Share

The IX Biopharma earnings per share therefore indicates how much revenue IX Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IX Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IX Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IX Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IX Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IX Biopharma Revenue, EBIT and net profit per share

DateIX Biopharma Sales per ShareIX Biopharma EBIT per shareIX Biopharma Earnings per Share
2025e0.03 undefined0 undefined0.01 undefined
20240.01 undefined-0.01 undefined-0.01 undefined
20230.01 undefined-0.01 undefined-0.01 undefined
20220.02 undefined0 undefined-0.01 undefined
20210 undefined-0.01 undefined-0.01 undefined
20200 undefined-0.02 undefined-0.02 undefined
20190 undefined-0.02 undefined-0 undefined
20180 undefined-0.02 undefined-0.02 undefined
20170.01 undefined-0.01 undefined-0.01 undefined
20160.01 undefined-0.01 undefined-0.01 undefined
20150.01 undefined-0.02 undefined-0.02 undefined
20140 undefined-0.01 undefined-0.01 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0 undefined-0 undefined

IX Biopharma business model

IX Biopharma Ltd is a leading biopharmaceutical company based in Singapore. The company was founded in 2007 by Dr. Jan-Olof Heldin, a globally recognized biotech entrepreneur. The history of IX Biopharma dates back to the late 90s, when Dr. Heldin began working on a new method of drug delivery called "Oral Transmucosal Technology" (OTM). This technology allows for the development of drugs that can quickly and specifically penetrate the body, with a very high bioavailability. Today, IX Biopharma has a strong presence in the market for novel OTM-based drugs. The company operates in three different business areas: human medicine products, animal health, and life sciences. IX Biopharma's human medicine products are specialized in the treatment of pain and inflammation. The company has already launched a product - a fast-acting spray for pain relief. This new technology allows the medication to quickly enter the body and take effect, providing patients with rapid pain relief. IX Biopharma is currently working on additional products based on OTM technology to provide suitable solutions for other medical conditions as well. In the animal health sector, IX Biopharma offers veterinary products tailored to the needs of pets and livestock. The company collaborates closely with veterinarians and livestock experts to develop innovative therapies and treatment methods customized for specific animal needs. In the field of life sciences, IX Biopharma engages in a wide range of activities and services. These include the development of diagnostic products, conducting clinical trials, identifying biomarkers, and developing immunotherapies. Overall, IX Biopharma is an innovative biopharmaceutical company specializing in the development of drugs based on new technologies. The company is constantly striving to find innovative solutions to improve the health of humans and animals. With a dedicated team of scientists and researchers, as well as a strong presence in Asia and Europe, IX Biopharma is a pioneer in the new world of OTM-based drug development. IX Biopharma is one of the most popular companies on Eulerpool.com.

IX Biopharma SWOT Analysis

Strengths

IX Biopharma Ltd has a strong portfolio of innovative pharmaceutical products that cater to a diverse range of therapeutic areas. These products have shown promising results in clinical trials, showcasing the company's strong research and development capabilities.

The company has established strategic partnerships with leading healthcare organizations, enabling IX Biopharma Ltd to leverage their extensive networks and resources for market expansion, distribution, and access to new markets.

IX Biopharma Ltd has a robust intellectual property portfolio, providing protection for their innovative drug formulations and delivery technologies. This strengthens the company's competitive position and offers barriers to entry for potential competitors.

Weaknesses

One of the challenges IX Biopharma Ltd faces is the dependency on a limited number of key customers. This can expose the company to potential risks if any of these customers significantly reduce their orders or switch to alternative suppliers.

The company has relatively limited financial resources compared to some of its competitors, which may restrict their ability to invest in new product development initiatives or expand market presence at the desired pace.

There might be a lack of brand awareness and recognition in certain geographical markets, which could pose difficulties in penetrating these regions and competing effectively against established pharmaceutical companies.

Opportunities

The increasing prevalence of various diseases and the growing demand for novel pharmaceutical solutions present significant opportunities for IX Biopharma Ltd to expand its market share and generate substantial revenue growth.

The company can capitalize on advancements in technology and scientific research to develop new and improved drug delivery systems, maximizing the effectiveness and convenience of their pharmaceutical products.

Emerging markets, particularly in developing countries, offer untapped potential for IX Biopharma Ltd to establish a stronger presence and capture a larger customer base by offering affordable yet quality healthcare solutions.

Threats

The pharmaceutical industry is highly regulated, and changes in regulations or pricing policies imposed by regulatory authorities could impact IX Biopharma Ltd's operations, cost structure, and profitability.

Intense competition within the industry from established pharmaceutical companies and new entrants poses a threat to IX Biopharma Ltd's market position and revenue growth. The company needs to continuously innovate and differentiate its products to stay ahead.

Economic uncertainties and volatility may affect consumer spending patterns, leading to reduced demand for pharmaceutical products and potential challenges in maintaining steady revenue streams.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IX Biopharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IX Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IX Biopharma shares outstanding

The number of shares was IX Biopharma in 2024 — This indicates how many shares 767.358 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IX Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IX Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IX Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IX Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for IX Biopharma.

IX Biopharma shareholders

%
Name
Stocks
Change
Date
28.27896 % Lee (Yip Hang Eddy)217,000,85209/4/2024
8.69842 % HRT Corporation Pte. Ltd.66,748,02909/4/2024
2.97040 % Tang (Choy Leng Jane)22,793,56509/4/2024
2.70109 % Narulla (Jaspal Singh)20,727,0473,737,6649/4/2024
2.27675 % Tan (See Tee)17,470,800914,9009/4/2024
2.17971 % C2C Biopharma Holdings Pte. Ltd.16,726,2003,016,2009/4/2024
2.00858 % Chan (Hwee Hoon)15,413,0272,360,9149/4/2024
1.99036 % Wetwaters 8 S Pte. Ltd.15,273,1802,754,1809/4/2024
1.97624 % Seah (Boon Lock)15,164,86909/4/2024
1.47259 % Sng (Beng Hock Michael)11,300,0005,650,0009/4/2024
1
2

IX Biopharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
JD com A Stock
JD com A
SupplierCustomer-0,520,490,410,810,69
Seelos Therapeutics Stock
Seelos Therapeutics
SupplierCustomer-0,71-0,120,390,820,920,23
Alibaba Group Holding Stock
Alibaba Group Holding
SupplierCustomer-0,730,110,450,800,860,74
1

Most common questions regarding IX Biopharma

What values and corporate philosophy does IX Biopharma represent?

IX Biopharma Ltd represents values of innovation, excellence, and commitment to health care. With a strong corporate philosophy focused on leveraging cutting-edge technologies, IX Biopharma is dedicated to developing innovative pharmaceutical and biotech solutions that improve patients' lives. The company's research and development efforts prioritize breakthrough therapies, ensuring the highest standards of safety and efficacy. By consistently implementing rigorous scientific methodologies and upholding ethical standards, IX Biopharma aims to transform healthcare by addressing unmet medical needs. Through its continuous pursuit of scientific advancements, the company is committed to creating value for both patients and stakeholders.

In which countries and regions is IX Biopharma primarily present?

IX Biopharma Ltd is primarily present in Singapore.

What significant milestones has the company IX Biopharma achieved?

IX Biopharma Ltd has achieved several significant milestones since its establishment. The company has successfully developed innovative pharmaceutical products and brought them to market. IX Biopharma Ltd has received regulatory approvals for its flagship product, Wafermine, which is a unique sublingual wafer for the treatment of pain and other conditions. The company has also entered into strategic partnerships and collaborations with renowned organizations to further enhance its research and development capabilities. Moreover, IX Biopharma Ltd has expanded its global presence by securing international licensing and distribution agreements. These accomplishments demonstrate the company's commitment to advancing healthcare solutions and driving growth in the biopharmaceutical industry.

What is the history and background of the company IX Biopharma?

IX Biopharma Ltd is a prominent pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in [year], IX Biopharma has a rich history of catering to the global healthcare industry by providing cutting-edge solutions. The company focuses on leveraging its expertise in proprietary drug delivery platforms to enhance drug efficacy and patient compliance. IX Biopharma boasts an impressive portfolio of products and pipeline candidates across various therapeutic areas. With a commitment to pushing boundaries in pharmaceutical innovation, IX Biopharma continues to pave the way for groundbreaking advancements in patient care and treatment options.

Who are the main competitors of IX Biopharma in the market?

The main competitors of IX Biopharma Ltd in the market are other pharmaceutical companies operating in the biopharmaceutical sector. Some notable competitors include larger established companies such as Pfizer, Novartis, and Johnson & Johnson, as well as smaller biotech firms like Moderna and Gilead Sciences. These competitors strive to develop and market innovative drugs and therapies, often targeting similar disease areas or therapeutic indications. The competitive landscape in the biopharmaceutical sector is highly complex and dynamic, with constant advancements in research and development shaping the market dynamics.

In which industries is IX Biopharma primarily active?

IX Biopharma Ltd is primarily active in the pharmaceutical industry.

What is the business model of IX Biopharma?

The business model of IX Biopharma Ltd is focused on the research, development, and commercialization of innovative pharmaceutical products. The company specializes in novel drug delivery technologies and therapeutic formulations. IX Biopharma aims to create value by continuously developing and improving its proprietary drug delivery platforms, such as WaferiX™ and Buccal Adhesive Tablets (BAT), which offer enhanced drug delivery and patient compliance. Through collaborations and partnerships, IX Biopharma strives to bring its advanced pharmaceutical solutions to market, addressing unmet medical needs and improving treatment options for various diseases and conditions.

What is the P/E ratio of IX Biopharma 2025?

The IX Biopharma P/E ratio is 2.41.

What is the P/S ratio of IX Biopharma 2025?

The IX Biopharma P/S ratio is 0.63.

What is the Quality Investing of IX Biopharma?

The Quality Investing for IX Biopharma is 5/10.

What is the revenue of IX Biopharma 2025?

The expected IX Biopharma revenue is 24.28 M SGD.

How high is the profit of IX Biopharma 2025?

The expected IX Biopharma profit is 6.36 M SGD.

What is the business model of IX Biopharma

IX Biopharma Ltd is a Singapore-based company that specializes in the development and marketing of innovative therapies for neuropsychiatric disorders. The company offers a wide range of products and services based on the latest scientific knowledge. The business model of IX Biopharma is based on three pillars: research and development, production, and marketing of pharmaceuticals and health products. Research and development is the core of IX Biopharma's business model. The company continuously invests in developing new and innovative compounds and therapies for the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety disorders, and ADHD. IX Biopharma collaborates closely with leading research institutions and experts in this field. The second pillar of IX Biopharma's business model is the production of pharmaceuticals and health products. The company relies on modern production technologies and strict quality standards to ensure that its products meet the highest requirements. Currently, IX Biopharma offers a wide range of products, including prescription and over-the-counter drugs, dietary supplements, and herbal remedies. The third pillar of IX Biopharma's business model is the marketing of its products. The company employs a comprehensive multi-channel strategy that allows the distribution of its products through various channels, including pharmacies, doctors, online shops, and other retailers. The company uses a targeted and audience-specific marketing strategy to raise awareness about its products and increase sales. One of IX Biopharma's key products is Wafermine, a medication used for the treatment of schizophrenia and other neuropsychiatric disorders. Wafermine is a novel drug developed based on Ibuprofen and offers a promising approach to treating these conditions due to its unique mechanism of action. The company is currently working on developing additional products such as dietary supplements and herbal remedies to expand its product portfolio and strengthen its position in the market. Overall, IX Biopharma's business model aims to gain a competitive advantage and achieve long-term growth by developing and marketing innovative compounds and therapies for neuropsychiatric disorders. The company relies on scientific excellence, cutting-edge technologies, and a targeted marketing strategy to achieve its goals.

What is the IX Biopharma dividend?

IX Biopharma pays a dividend of 0 SGD distributed over payouts per year.

How often does IX Biopharma pay dividends?

The dividend cannot currently be calculated for IX Biopharma or the company does not pay out a dividend.

What is the IX Biopharma ISIN?

The ISIN of IX Biopharma is SG1BD9000009.

What is the IX Biopharma ticker?

The ticker of IX Biopharma is 42C.SI.

How much dividend does IX Biopharma pay?

Over the past 12 months, IX Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IX Biopharma is expected to pay a dividend of 0 SGD.

What is the dividend yield of IX Biopharma?

The current dividend yield of IX Biopharma is .

When does IX Biopharma pay dividends?

IX Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IX Biopharma?

IX Biopharma paid dividends every year for the past 0 years.

What is the dividend of IX Biopharma?

For the upcoming 12 months, dividends amounting to 0 SGD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IX Biopharma located?

IX Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von IX Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IX Biopharma from 8/15/2025 amounting to 0 SGD, you needed to have the stock in your portfolio before the ex-date on 8/15/2025.

When did IX Biopharma pay the last dividend?

The last dividend was paid out on 8/15/2025.

What was the dividend of IX Biopharma in the year 2024?

In the year 2024, IX Biopharma distributed 0 SGD as dividends.

In which currency does IX Biopharma pay out the dividend?

The dividends of IX Biopharma are distributed in SGD.

All fundamentals about IX Biopharma

Our stock analysis for IX Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IX Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.